Application of gallic acid derivative in inhibition of growth process of calcium oxalate monohydrate crystal

By using methyl gallate or ethyl gallate in a calcium oxalate supersaturated solution, the growth of calcium oxalate monohydrate crystals is inhibited, its morphology is changed and its adhesion to cells is reduced, calcium oxalate stones in the prior art are solved. The problems of formation and kidney damage have achieved stronger inhibitory effects.

CN119033752APending Publication Date: 2024-11-29TIANJIN UNIV +1
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410956019.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing calcium oxalate crystal regulators have poor inhibitory effect on calcium oxalate monohydrate, and the gallic acid derivatives have poor stability in hydrated air, which cannot effectively prevent the formation of calcium oxalate stones and kidney damage.

Method used

Using specific methyl gallate or ethyl gallate, by adding sodium oxalate and calcium chloride to the supersaturated calcium oxalate solution, the solution supersaturation and flow rate are controlled, the growth of calcium oxalate monohydrate crystals is inhibited, and the growth of calcium oxalate monohydrate crystals is changed. Topomorphism and reduce adhesion to cells.

Benefits of technology

It significantly inhibits the growth of calcium oxalate monohydrate crystals, reduces the deposition of crystals in the kidneys and damage to cells, and has a stronger effect in preventing the formation of calcium oxalate stones, which is better than existing substances.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033752A_ABST
    Figure CN119033752A_ABST
Patent Text Reader

Abstract

The invention provides an application of a gallic acid derivative in inhibition of growth of calcium oxalate monohydrate crystals, the gallic acid derivative comprises methyl gallate or ethyl gallate, and the growth inhibition process comprises the following steps: adding sodium oxalate and calcium chloride into a gallic acid derivative solution; enabling the degree of supersaturation of calcium oxalate in the solution to be 5-15, crystallizing at 20-50 DEG C for 20-100 hours, and observing the growth condition of calcium oxalate monohydrate crystals. Methyl gallate or ethyl gallate specifically inhibits growth of a calcium oxalate monohydrate crystal in the long axis direction, so that the length-diameter ratio of the crystal is reduced, the crystal morphology is changed, the growth of the calcium oxalate monohydrate crystal can be efficiently inhibited, the area of the crystal face (100) of the crystal can be reduced, and the inhibition effect is better than that of existing found substances.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomineralization and relates to the application of a gallic acid derivative in the process of inhibiting the growth of calcium oxalate monohydrate crystals. Background Art

[0002] Biomineralization of calcium oxalate is ubiquitous in nature. Calcium oxalate crystals of different shapes and sizes exist in plants to support their structures and provide a source of calcium for life activities. However, the mineralization of calcium oxalate in animals or humans can induce diseases such as kidney stones, seriously affecting people's normal lives.

[0003] There are currently three types of calcium oxalate hydrates, namely monohydrate (COM), dihydrate (COD) and trihydrate (C OT). The monohydrate has a hexagonal rhombus crystal habit, the dihydrate has a bipyramidal morphology, and the trihydrate has a hexagonal flake morphology. Calcium oxalate monohydrate and dihydrate are mainly present in urine. The monohydrate can adhere to renal epithelial cells and macromolecules in urine, and studies have found that the crystal face (100) of the monohydrate has the strongest adhesion to renal epithelial cells. As the number of adhered crystals increases, they will aggregate to form large particles, making them unable to be excreted, and they will be retained in the kidneys and eventually form stones.

[0004] The existing calcium oxalate crystal modifiers include metal ions (K + ,Zn 2+ Mg 2+ ) etc., small organic molecules (citric acid, hydroxycitric acid), and macromolecules (peptides, proteins, polymers, etc.). These substances have a certain inhibitory effect on the nucleation and growth of calcium oxalate monohydrate, but the inhibitory effect of these molecules is not ideal and needs to be improved.

[0005] Gallic acid protected by recent patents has poor stability and is easily oxidized and ineffective in hydrated air. Therefore, a stable and efficient calcium oxalate crystallization regulator is needed. Existing patented gallic acid derivatives only have a regulatory effect on the nucleation and growth of calcium oxalate crystals, and only focus on the effect of the regulator in vitro. The adhesion of crystals to cells in the body is a key factor in the formation of kidney stones, which can directly cause cell damage, cause them to secrete pro-inflammatory factors, aggravate the adhesion between crystals, form larger aggregates and eventually remain in the body. Gallic acid derivatives have strong anti-inflammatory effects, thereby reducing crystal deposition and kidney damage in the body. Therefore, it is necessary to use certain means to inhibit the growth of calcium oxalate monohydrate crystals and reduce aggregation / adhesion phenomena, so as to reduce the deposition of crystals in the body and damage to cells, and achieve a preventive effect. Summary of the invention

[0006] The present invention aims to provide an application of a gallic acid derivative in inhibiting the growth of calcium oxalate monohydrate crystals. The use of specific methyl gallate or ethyl gallate can not only change the morphology of calcium oxalate monohydrate, but also effectively inhibit the growth of calcium oxalate monohydrate crystals, and has a stronger inhibitory effect than the existing discovered substances, thereby preventing the formation of calcium oxalate stones.

[0007] The methyl gallate and ethyl gallate (structures shown below) disclosed in the present invention can inhibit the growth of calcium oxalate monohydrate when calcium oxalate is supersaturated.

[0008]

[0009] In the present invention, the gallic acid derivative inhibits the growth of calcium oxalate monohydrate crystals in the following process:

[0010] Sodium oxalate and calcium chloride are added to the gallic acid derivative solution so that the supersaturation of calcium oxalate in the solution is 5-15, and crystallization is carried out at 20-50° C. for 20-100 hours, thereby inhibiting the growth of calcium oxalate monohydrate crystals.

[0011] When the gallic acid derivative is methyl gallate, the concentration of the gallic acid derivative solution is 5-100 μmol / L.

[0012] When the gallic acid derivative is ethyl gallate, the concentration of the gallic acid derivative solution is 100-400 μmol / L.

[0013] In the present invention, the molar ratio of calcium ions to oxalate ions in the sodium oxalate and calcium chloride is 1:1-6:1.

[0014] In the present invention, during the inhibition process, saturated solutions of sodium oxalate and calcium chloride are introduced at a constant flow rate to maintain a constant supersaturation in the system. In this process, the gallic acid derivative inhibits the growth of calcium oxalate monohydrate crystals, and the solution flow rate is controlled at 1-50 mL / h.

[0015] In the present invention, the observation of the growth of calcium oxalate monohydrate crystals includes the growth morphology and the growth rate in different directions, wherein:

[0016] Topography tests include:

[0017] (1) Use polarizing microscopy to photograph the morphology of calcium oxalate crystals and analyze the (100) crystal plane of 50–100 crystals.

[0018] (2) Measure the lengths of the long axis

[010] and the short axis

[001] of the (100) crystal plane and calculate the aspect ratio (AspectRatio):

[0019]

[0020] Among them, Length

[010] is the length in the long axis direction; Width

[001] is the length in the short axis direction.

[0021] Growth rate test methods include:

[0022] The growth rate of calcium oxalate crystals in different directions was obtained by in situ observation under an inverted microscope.

[0023] In the present invention, the gallic acid derivative is used in the preparation of a drug for preventing and / or treating kidney stones.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] The invention selects specific methyl gallate or ethyl gallate to specifically inhibit the growth of calcium oxalate monohydrate crystals along the long axis direction, resulting in a decrease in the aspect ratio of the crystals and a change in the crystal morphology. Methyl gallate or ethyl gallate can effectively inhibit the growth of calcium oxalate monohydrate crystals, reduce the area of ​​the crystal (100) plane, and have a stronger inhibitory effect than existing substances that have been discovered.

[0026] The present invention verifies through experiments that ethyl gallate has the strongest ability to inhibit crystal growth. Similar to gallic acid, the trihydroxy structure of the molecule promotes its stable adsorption on the surface of calcium oxalate monohydrate crystals. On this basis, the ethyl ester group replaces the carboxylic acid on the side chain, further hindering the adsorption of calcium ions / oxalate ions on the crystal surface through the steric hindrance effect.

[0027] The present invention verifies through cell experiments and animal experiments that ethyl gallate can effectively inhibit the adhesion of calcium oxalate monohydrate crystals on renal tubular epithelial cells, reduce the deposition of crystals in the kidneys and the damage of crystals to kidney tissues, and thus prevent the formation of kidney stones. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The crystal morphology of calcium oxalate monohydrate without adding gallic acid derivatives has a higher aspect ratio.

[0029] Figure 2 The crystal morphology of calcium oxalate monohydrate under the action of gallic acid derivatives, which are gallic acid (a), methyl gallate (b), ethyl gallate (c), and propyl gallate (d). Compared with the crystal morphology without the addition of gallic acid derivatives, the growth along the

[001] direction (long axis direction) is inhibited and the aspect ratio is reduced.

[0030] Figure 3The crystals adhered to the cells before and after the action of ethyl gallate. After the addition of ethyl gallate, the number of calcium oxalate monohydrate crystals adhered to the renal tubular epithelial cells was significantly reduced.

[0031] Figure 4 The kidney sections of mice before and after ethyl gallate injection. After intraperitoneal injection of ethyl gallate, the amount of crystals deposited in the kidneys was significantly reduced.

[0032] Figure 5 The kidney sections of mice were stained with PAS before and after ethyl gallate injection. After intraperitoneal injection of ethyl gallate, renal tubular damage was alleviated. DETAILED DESCRIPTION

[0033] It should be noted that the following detailed descriptions are all exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs. The technical scheme of the present invention is further illustrated below by specific embodiments. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0034] Example 1

[0035] Methyl gallate changes the crystal morphology of calcium oxalate monohydrate

[0036] In 25 ml of deionized water, the dosage of methyl gallate was 41, 81, 201 μmol / L, and the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The whole system was kept still and kept at 37°C for 72 hours to obtain calcium oxalate monohydrate crystals. Methyl gallate affects the morphology of calcium oxalate monohydrate crystals, such as Figure 2 As shown in (b), the growth of the crystal along the long axis

[010] is suppressed. The aspect ratio of the long axis

[010] to the short axis

[001] is measured and the Aspect Ratio is calculated using the following formula.

[0037]

[0038] From the data, it can be seen that methyl gallate has the strongest inhibition on the (100) crystal plane, and the inhibition increases with the increase of concentration, and the aspect ratio is reduced to a maximum of 1.229.

[0039] Table 1 Inhibition of aspect ratio of calcium oxalate by methyl gallate

[0040]

[0041] Example 2

[0042] Ethyl gallate changes the crystal morphology of calcium oxalate monohydrate

[0043] In 25 ml of deionized water, the dosage of ethyl gallate was 38, 76, and 187 μmol / L, respectively, and the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The whole system was kept still and kept at 37°C for 72 hours to obtain calcium oxalate monohydrate crystals. Ethyl gallate affects the morphology of calcium oxalate monohydrate crystals, such as Figure 2 As shown in (c), the growth of the crystal along the long axis

[010] direction is suppressed. The aspect ratio of the long axis

[010] and the short axis

[001] is measured and the Aspect Ratio is calculated using the following formula.

[0044]

[0045] From the data, it can be seen that the inhibition of ethyl gallate on the (100) crystal plane increases with the increase of concentration, and the aspect ratio is reduced to a maximum of 1.442.

[0046] Table 2 Inhibition of the aspect ratio of calcium oxalate by ethyl gallate

[0047]

[0048] Comparative Example 1

[0049] Growth of calcium oxalate monohydrate crystals under blank conditions

[0050] The growth solution is passed into a crystal growth tank filled with calcium oxalate. Without adding any inhibitor molecules, the morphology is as follows: Figure 1 The growth solution was introduced at a flow rate of 25 ml / h, wherein the supersaturation of calcium oxalate was controlled at S=1 (Ca 2 + :C2O4 2- =1:1). The crystals grew for 2 hours, and the length and width of the (100) crystal plane were recorded every 10 minutes. A linear fit was performed with time to obtain the growth rate R of the long axis

[010] direction of the calcium oxalate crystal under blank conditions. control It is 3.109μm / h.

[0051] Comparative Example 2

[0052] Gallic acid changes the crystal morphology of calcium oxalate monohydrate

[0053] In 25 ml of deionized water, the dosage of gallic acid was 22, 44, and 108 μmol / L, and the supersaturation of calcium oxalate was controlled at S=1 (Ca2+ :C2O4 2- =1:1). The whole system was kept still and kept at 37°C for 72 hours to obtain calcium oxalate monohydrate crystals. Gallic acid affects the morphology of calcium oxalate monohydrate crystals, such as Figure 2 As shown in (a), the growth of the crystal along the long axis

[010] is suppressed. The aspect ratio is measured between the length of the long axis

[010] and the length of the short axis

[001] , and the Aspect Ratio is calculated using the following formula.

[0054]

[0055] From the data, it can be seen that the inhibitory effect of gallic acid on the (100) crystal plane increases with the increase of concentration, and the aspect ratio is reduced to a maximum of 1.630.

[0056] Table 4 Inhibition of aspect ratio of calcium oxalate by gallic acid

[0057]

[0058] Comparative Example 3

[0059] Propyl gallate changes the crystal morphology of calcium oxalate monohydrate

[0060] In 25 ml of deionized water, the dosage of propyl gallate was 35, 70, and 145 μmol / L, respectively, and the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The whole system was kept still and kept at 37°C for 72 hours to obtain calcium oxalate monohydrate crystals. Propyl gallate affects the morphology of calcium oxalate monohydrate crystals, such as Figure 2 As shown in (d), the growth of the crystal along the long axis

[010] direction is suppressed. The aspect ratio of the long axis

[010] and the short axis

[001] is measured and the Aspect Ratio is calculated using the following formula.

[0061]

[0062] From the data, it can be seen that the inhibition of propyl gallate on the (100) crystal plane increases with the increase of concentration, and the aspect ratio is reduced to a maximum of 1.81.

[0063] Table 3 Inhibition of the aspect ratio of calcium oxalate by propyl gallate

[0064]

[0065] Example 3

[0066] Control of the Growth of Calcium Oxalate Monohydrate Crystals by Methyl Gallate

[0067] A growth solution containing 21, 41, 81, 201, or 395 μmol / L of methyl gallate was introduced into a crystal growth tank containing calcium oxalate. The growth solution was introduced at a flow rate of 25 ml / h, wherein the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The crystals grew for 2 h, and the length and width of the (100) crystal plane were recorded every 10 min. The growth rate under the action of the inhibitor was obtained by linear fitting with time. The RIP value calculated by the following formula is shown in Table 5.

[0068]

[0069] From the data, it can be seen that methyl gallate can control the growth of calcium oxalate, and the control effect increases with the increase of dosage. The effect is stronger than gallic acid, reaching an inhibitory effect of 74.9% at high dosage.

[0070] Table 5 Control data of methyl gallate on calcium oxalate growth (

[001] direction, length)

[0071]

[0072] Example 4

[0073] Control of the Growth of Calcium Oxalate Monohydrate Crystals by Ethyl Gallate

[0074] A growth solution containing 19, 38, 76, 187, or 376 μmol / L of ethyl gallate was introduced into a crystal growth tank containing calcium oxalate. The growth solution was introduced at a flow rate of 25 ml / h, wherein the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The crystals were grown for 2 h, and the length and width of the (100) crystal plane were recorded every 10 min. The growth rate under the action of the inhibitor was obtained by linear fitting with time. The RIP value calculated by the following formula is shown in Table 6.

[0075]

[0076] From the data, it can be seen that ethyl gallate can control the growth of calcium oxalate, and the control effect increases with the increase of dosage. The effect is much better than gallic acid, reaching an inhibition effect of 89.6% at high dosage.

[0077] Table 6 Control data of ethyl gallate on calcium oxalate growth (

[001] direction, length)

[0078]

[0079] Comparative Example 4

[0080] Growth of calcium oxalate monohydrate crystals under blank conditions

[0081] The growth solution was introduced into the crystal growth tank containing calcium oxalate. The growth solution was introduced at a flow rate of 25 ml / h, wherein the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The crystals grew for 2 hours, and the length and width of the (100) crystal plane were recorded every 10 minutes. A linear fit was performed with time to obtain the growth rate R of the long axis

[010] direction of the calcium oxalate crystal under blank conditions. control It is 3.109μm / h.

[0082] Comparative Example 5

[0083] Gallic acid controls the growth of calcium oxalate monohydrate crystals

[0084] A growth solution with 11, 22, 44, 108, or 214 μmol / L gallic acid added was introduced into a crystal growth tank containing calcium oxalate. The growth solution was introduced at a flow rate of 25 ml / h, wherein the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The crystals grew for 2 h, and the length of the (100) crystal plane was recorded every 10 min. A linear fit was performed with time to obtain the growth rate under the action of the inhibitor. The RIP value calculated using the following formula is shown in Table 8.

[0085]

[0086] From the data, it can be seen that gallic acid can control the growth of calcium oxalate, and the control effect increases with the increase of dosage, reaching an inhibitory effect of 67.7% at high dosage.

[0087] Table 8 Gallic acid control data on calcium oxalate growth (

[001] direction, length)

[0088]

[0089]

[0090] Comparative Example 6

[0091] Propyl Gallate Controls the Growth of Calcium Oxalate Monohydrate Crystals

[0092] A growth solution containing 18, 35, 70, 145, or 343 μmol / L of propyl gallate was introduced into a crystal growth tank containing calcium oxalate. The growth solution was introduced at a flow rate of 25 ml / h, wherein the supersaturation of calcium oxalate was controlled at S=1 (Ca2+ :C2O4 2- =1:1). The crystal grew for 2 h, and the length and width of the (100) crystal plane were recorded every 10 min. The growth rate under the action of the inhibitor was obtained by linear fitting with time. The RIP value calculated by the following formula is shown in Table 7.

[0093]

[0094] From the data, it can be seen that propyl gallate can achieve growth control on calcium oxalate, and the control effect increases with the increase of dosage, which is similar to the control effect of gallic acid, reaching an inhibitory effect of 64.9% at high dosage.

[0095] Table 7 Control data of propyl gallate on calcium oxalate growth (

[001] direction, length)

[0096]

[0097] Comparative Example 7

[0098] Citric acid controls the growth of calcium oxalate monohydrate crystals

[0099] A growth solution with 78 μmol / L citric acid added was introduced into a crystal growth tank containing calcium oxalate. The growth solution was introduced at a flow rate of 25 ml / h, wherein the supersaturation of calcium oxalate was controlled at S=1 (Ca 2+ :C2O4 2- =1:1). The crystal grew for 2 hours, and the length and width of the (100) crystal plane were recorded every 10 minutes. The growth rate under the action of the inhibitor was obtained by linear fitting with time. The RIP value calculated by the following formula was 50.334.

[0100]

[0101] From the above data, it can be seen that at a concentration of 70-80 μmol / L, the inhibitory effect of the small molecule inhibitor reaches a threshold, and the inhibitory effect of citric acid at this concentration is 50.3%.

[0102] Test Example 1

[0103] Gallic acid, methyl gallate, ethyl gallate, and propyl gallate were tested for controlling the adhesion of calcium oxalate monohydrate crystals on cells.

[0104] 100 μg / ml COM crystals were placed on a plate with human renal tubular epithelial cells, and 100 μg / ml ethyl gallate was added. After the crystals adhered to the cells for 12 hours, they were washed three times with PBS buffer, and the number of crystals adhered to the cells in a random field of view was observed under a microscope.

[0105] like Figure 3 As shown in the figure, compared with the blank control, ethyl gallate EG significantly reduced the adhesion of calcium oxalate monohydrate crystals on cells. Figure 3 The statistical data showed that under the action of 100 μg / ml ethyl gallate (EG), the number of crystals attached to the cells was reduced to 50%.

[0106] Test Example 2

[0107] Ethyl gallate was tested for its ability to prevent kidney stone formation in mice.

[0108] The mice in the kidney stone model group were injected with 75 mg / kg body weight of glyoxylic acid (Gly) for 6 consecutive days; the mice in the control group were injected with 10 mg / kg and 30 mg / kg body weight of ethyl gallate (EG) and 75 mg / kg body weight of glyoxylic acid (Gly) for 6 consecutive days; the mice in the drug control group were injected with 30 mg / kg body weight of citric acid (CA) and 75 mg / kg body weight of glyoxylic acid (Gly) for 6 consecutive days.

[0109] Figure 4 The statistical data in the results show that the injection of ethyl gallate effectively prevented the deposition of crystals in the kidneys of mice. Figure 4 As shown in the kidney sections taken with a polarizing microscope, 75 mg / kg of glyoxylic acid deposited a large number of crystals in the mouse kidneys ( Figure 4 , Gly); at the same time, 10 mg / kg concentration of ethyl gallate ( Figure 4 , Gly+10EG), significantly reduced the amount of crystals deposited in the kidneys (reduced by 75%), and was more effective than the commercially available kidney stone prevention drug citric acid ( Figure 4 , Gly+30CA).

[0110] Test Example 3

[0111] To test the protective effect of ethyl gallate against crystalloid-induced renal injury.

[0112] The mice in the kidney stone model group were injected with 75 mg / kg body weight of glyoxylic acid (Gly) for 6 consecutive days, the mice in the control group were injected with 10 mg / kg body weight of ethyl gallate (EG) and 75 mg / kg body weight of glyoxylic acid (Gly) for 6 consecutive days, and the mice in the blank group were injected with 10 mg / kg body weight of ethyl gallate (EG) for 6 consecutive days.

[0113] Kidney sections were stained with PAS. Figure 5 As shown in Figure 2, tubular injury was quantified by analysis of histological markers such as tubular cell loss, brush border loss, and tubular lumen dilation. Figure 5As shown in the statistics, the kidney tissue of mice that formed kidney stones after glyoxylic acid injection showed obvious damage and atrophy ( Figure 5 , Gly); after simultaneous injection of ethyl gallate, only a small area of ​​renal tissue was damaged and atrophied ( Figure 5 , Gly+10EG, Gly+30EG), and the effect is better than the commercially available drug citric acid ( Figure 5 , Gly+30CA); injection of ethyl gallate alone did not cause any damage to kidney tissue ( Figure 5 , EG).

[0114] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. Application of a gallic acid derivative in inhibiting the growth of calcium oxalate monohydrate crystals, It is characterized in that The gallic acid derivatives include methyl gallate or ethyl gallate.

2. The use according to claim 1, It is characterized in that The gallic acid derivative inhibits the growth of calcium oxalate monohydrate crystals, comprising: Sodium oxalate and calcium chloride are added to the gallic acid derivative solution so that the supersaturation of calcium oxalate in the solution is 5-15, and crystallization is carried out at 20-50° C. for 20-100 hours, and the growth of calcium oxalate monohydrate crystals is observed.

3. The use according to claim 2, It is characterized in that When the gallic acid derivative is methyl gallate, the concentration of the gallic acid derivative solution is 5-100 μmol / L.

4. The use according to claim 2, It is characterized in that When the gallic acid derivative is ethyl gallate, the concentration of the gallic acid derivative solution is 100-400 μmol / L.

5. The use according to claim 2, It is characterized in that The molar ratio of calcium ions to oxalate ions in the sodium oxalate and calcium chloride is 1:1-6:

1.

6. The use according to claim 2, It is characterized in that The observation of the growth of calcium oxalate monohydrate crystals includes growth morphology and growth rates in different directions.

7. The use according to claim 1, It is characterized in that The gallic acid derivative is used in preparing a medicine for preventing and / or treating kidney stones.

Citation Information

Cited By

  • Soft tissue filling preparation containing calcium oxalate particles as well as preparation method and application of soft tissue filling preparation

    CN119925714A

  • Polarized light microscopic quantification method for calcium oxalate crystals in ginseng

    CN120558956A

  • A polarized microscopic quantitative method for calcium oxalate crystals in ginseng

    CN120558956B